Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome

Glueck, Charles J.; Wang, Ping; Fontaine, R; Sieve-Smith, Luann; Tracy, Trent; Moore, Sarah K.

doi:10.1016/s0026-0495(99)90250-0

Cited by 183 publications

(113 citation statements)

References 34 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Since there are data to suggest that PAI-1 is involved in luteolysis, modifying the reproductive potential, it could be intriguing to speculate on a dual role of elevated levels of PAI-1 in PCOS (22,23). In conclusion, the PCOS women had higher PAI-1 levels compared with the control group.…”

Section: Genotype Subgroups Controlsmentioning

confidence: 82%

The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels

Diamanti-Kandarakis

Palioniko

Alexandraki

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To investigate the prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovary syndrome (PCOS) and its functional significance. Design: Case-control study. Methods: We studied 98 patients and 64 controls. Body mass index (BMI) and waist-to-hip (WHR) ratio were determined. Blood samples were obtained for DNA analysis. PAI-1 plasma levels, serum total testosterone, fasting insulin and fasting glucose were measured and the glucose-to-insulin ratio was estimated in all subjects.Results: There was a statistically significant difference in the distribution of PAI-1 gene variations among the groups. The PCOS group had significantly higher 4G/4G and 4G/5G combinations than the control group, whereas there were significantly less 5G/5G. Among the PCOS women, 39.8% had the genotype 4G/4G, 39.8% 4G/5G and 20.4% 5G/5G. From the control group, 20.3% had genotype 4G/4G, 28.1% 4G/5G and 51.6% 5G/5G. In the 4G/4G genotype subgroup 75% were PCOS and 25% were controls, in the 4G/5G were 68.42% and 31.58% and in the 5G/5G were 31.58% and 62.26% respectively. The population of PCOS women had significantly higher PAI-1 levels, WHR, total testosterone, and fasting glucose than the population of controls. Conclusions: 1)The genotypic subtypes 4G/4G and 4G/5G, in PCOS, were present with a statistically higher frequency compared with controls. 2)PCOS women have higher levels of PAI-1 compared with the control group. 3)The presence of the 4G allele in PAI-1 promoter region of the gene further increases the PAI-1 levels. 150 793-798 European Journal of Endocrinology

show abstract

Section: Genotype Subgroups Controlsmentioning

confidence: 82%

The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels

Diamanti-Kandarakis

Palioniko

Alexandraki

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…PAI-1 activity is known to increase with elevating levels of serum insulin. Conversely, PAI-1 activity has been shown to decrease when insulin concentrations are reduced by metformin 20,46,48,49 . Glueck et al have postulated that by improving hyperinsulinemia, metformins reduction in PAI-1 activity reduces spontaneous pregnancy loss in PCOS.…”

Section: Resultsmentioning

confidence: 99%

The Pathophysiology of Miscarriage in Women with Polycystic Ovary Syndrome. Review and Proposed Hypothesis of Mechanisms Involved

Essah¹,

Cheang²,

Nestler³

2004

View full text Add to dashboard Cite

“…In other studies of women with PCOS, we have previously shown that the 4G4G PAI-1 mutation [19] was an independent determinant of serious pregnancy complications and that PAI-1 activity was an independent determinant of miscarriage [20][21][22][23] and recurrent pregnancy loss [24]. Elevated levels of PAI-1 have been associated with increased cardiovascular risk and increased thrombogenic tendency [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

Karadeniz

Erdoğan

Berdelı

et al. 2007

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Polycystic ovary syndrome (PCOS) is one of the most encountered endocrine malfunctions. PCOS patients have enhanced activation of the blood coagulation system. Methods Eighty-six young women with PCOS and 70 healthy control women were included in our study. PCOS patients and controls were matched for age, body mass index, and allele frequency. Genetic analysis of TPAI and PAI-1 were performed in all subjects. Results and conclusions No statistically significant differences have been detected about the ratios of genotypes resulting from PAI-1 promotor 4G/5G gene polymorphism. PAI-1 765 4G/5G gene polymorphism and TPA gene's Alurepeat insertion/deletion (I/D) polymorphism ratios were not different from the controls. In this study it is shown by the analysis of TPA gene's Alu-repeat insertion/deletion (I/D) polymorphism the PCOS patients with genotype II had lowers total cholesterol and LDL-cholesterol levels.

show abstract

Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome

Cited by 183 publications

References 34 publications

The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels

The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels

The Pathophysiology of Miscarriage in Women with Polycystic Ovary Syndrome. Review and Proposed Hypothesis of Mechanisms Involved

4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

Contact Info

Product

Resources

About